Table 3 Summary of outcomes for primary and secondary outcomes by intervention group

Outcome measure

Follow-up

n

Mean(SD)

Median(IQR)

Min–max

n

Mean(SD)

Median(IQR)

Min–max

6 min total distance

Baseline

4

360(84.98)

362(294.5–425.5)

259–457

8

369.63(78.39)

376.5(313.5–393)

266–525

6 months

1

255

255(255–255)

255–255

8

347.63(81.88)

369.5(288–388.5)

226–463

NSAA score

Consent

4

25.75(3.4)

26.5(23.5–28)

21–29

8

23.38(5.93)

22.5(18.5–29)

16–31

Baseline

4

26(4.55)

25.5(23–29)

21–32

8

24.13(5.49)

23.5(19.5–28.5)

18–32

6 months

2

21(15.56)

21(10–32)

10–32

8

21.38(8.47)

21(16–28)

8–33

FVC absolute

Consent

4

1.42(0.21)

1.43(1.27–1.57)

1.16–1.66

7

1.52(0.2)

1.5(1.27–1.74)

1.27–1.78

Baseline

2

1.29(0.21)

1.29(1.14–1.43)

1.14–1.43

5

1.34(0.19)

1.39(1.3–1.48)

1.03–1.5

6 months

0

5

1.33(0.42)

1.52(1–1.6)

0.77–1.76

FVC percent

Consent

2

90.5(9.19)

90.5(84–97)

84–97

4

97.25(11.62)

97.5(89–105.5)

83–111

Baseline

2

88.5(7.78)

88.5(83–94)

83–94

5

90.8(17.09)

91(79–101)

70–113

6 months

0

5

83.8(22.57)

88(68–93)

56–114

CHU utility value

Baseline

3

0.92(0.07)

0.89(0.87–1)

0.87–1

8

0.77(0.23)

0.88(0.59–0.94)

0.39–0.96

6 months

1

0.95

0.95(0.95–0.95)

0.95–0.95

8

0.87(0.09)

0.87(0.82–0.95)

0.71–1

CarerQol score

Baseline

3

31.27(10.37)

26.2(24.4–43.2)

24.4–43.2

7

40.6(22.9)

29.3(24.4–59.4)

19.7–81.6

6 months

1

50.1

50.1(50.1–50.1)

50.1–50.1

7

51.27(6.78)

50.1(48.8–50.4)

44–65.8

ACTIVLIM patient score

Baseline

3

32.67(9.71)

35(22–41)

22–41

8

30.38(7.58)

32(26.5–34)

17–41

6 months

1

21

21(21–21)

21–21

8

26.88(6.36)

26(22.5–31.5)

19–36

ACTIVLIM patient measure

Baseline

3

2.98(2.62)

4.15(−0.02–4.82)

−0.02–4.82

8

2.1(1.37)

2.22(1.61–2.78)

−0.6–4.15

6 months

1

0.18

0.18(0.18–0.18)

0.18–0.18

8

1.29(1.13)

1.48(0.4–2.1)

−0.35–2.73